Latest period
$57.5B
YoY change
+1.3%
5Y CAGR
-3.0%
Peak year (FY2017)
$45.2B
Latest annual
$33.9B
Total Liabilities history chart for Abbott Laboratories (ABT) from 2016 to 2025
Latest: $33.9B
Total Liabilities growth chart for Abbott Laboratories (ABT) from 2016 to 2025
Latest: +1.3%
Total Liabilities history table for Abbott Laboratories (ABT) from 1985 to 2025
| FY2025 | $33.9B | +1.3% | +$429M | ||
| FY2024 | $33.5B | -2.5% | -$874M | ||
| FY2023 | $34.4B | -8.4% | -$3.15B | ||
| FY2022 | $37.5B | -4.2% | -$1.64B | ||
| FY2021 | $39.2B | -0.9% | -$373M | ||
| FY2020 | $39.5B | +8.1% | +$2.96B | ||
| FY2019 | $36.6B | +0.4% | +$135M | ||
| FY2018 | $36.5B | -19.3% | -$8.7B | ||
| FY2017 | $45.2B | +41.3% | +$13.2B | ||
| FY2016 | $31.9B | +60.4% | +$12B | ||
| FY2015 | $19.9B | +1.5% | +$285M | ||
| FY2014 | $19.6B | +11.0% | +$1.95B | ||
| FY2013 | $17.7B | -56.2% | -$22.7B | ||
| FY2012 | $40.4B | +13.1% | +$4.67B | ||
| FY2011 | $35.8B | -3.3% | -$1.24B | ||
| FY2010 | $37B | +25.3% | +$7.47B | ||
| FY2009 | $29.5B | +18.4% | +$4.58B | ||
| FY2008 | $24.9B | +13.7% | +$3B | ||
| FY2007 | $21.9B | -0.9% | -$189M | ||
| FY2006 | $22.1B | +50.2% | +$7.4B | ||
| FY2005 | $14.7B | +2.0% | +$284M | ||
| FY2004 | $14.4B | +5.9% | +$799M | ||
| FY2003 | $13.6B | +0.4% | +$48.5M | ||
| FY2002 | $13.6B | -4.5% | -$642M | ||
| FY2001 | $14.2B | +112.1% | +$7.52B | ||
| FY2000 | $6.71B | -4.7% | -$331M | ||
| FY1999 | $7.04B | -6.1% | -$459M | ||
| FY1998 | $7.5B | +6.2% | +$440M | ||
| FY1997 | $7.06B | +12.0% | +$757M | ||
| FY1996 | $6.31B | +25.7% | +$1.29B | ||
| FY1995 | $5.02B | +12.1% | +$541M | ||
| FY1994 | $4.47B | +11.5% | +$461M | ||
| FY1993 | $4.01B | +11.7% | +$420M | ||
| FY1992 | $3.59B | +17.7% | +$541M | ||
| FY1991 | $3.05B | +11.8% | +$323M | ||
| FY1990 | $2.73B | +28.4% | +$604M | ||
| FY1989 | $2.13B | -10.0% | -$235M | ||
| FY1988 | $2.36B | +3.0% | +$68.3M | ||
| FY1987 | $2.29B | +9.8% | +$206M | ||
| FY1986 | $2.09B | +30.6% | +$489M | ||
| FY1985 | $1.6B | — | — |
- FY2025$33.9B+1.3%
- FY2024$33.5B-2.5%
- FY2023$34.4B-8.4%
- FY2022$37.5B-4.2%
- FY2021$39.2B-0.9%
- FY2020$39.5B+8.1%
- FY2019$36.6B+0.4%
- FY2018$36.5B-19.3%
- FY2017$45.2B+41.3%
- FY2016$31.9B+60.4%
- FY2015$19.9B+1.5%
- FY2014$19.6B+11.0%
- FY2013$17.7B-56.2%
- FY2012$40.4B+13.1%
- FY2011$35.8B-3.3%
- FY2010$37B+25.3%
- FY2009$29.5B+18.4%
- FY2008$24.9B+13.7%
- FY2007$21.9B-0.9%
- FY2006$22.1B+50.2%
- FY2005$14.7B+2.0%
- FY2004$14.4B+5.9%
- FY2003$13.6B+0.4%
- FY2002$13.6B-4.5%
- FY2001$14.2B+112.1%
- FY2000$6.71B-4.7%
- FY1999$7.04B-6.1%
- FY1998$7.5B+6.2%
- FY1997$7.06B+12.0%
- FY1996$6.31B+25.7%
- FY1995$5.02B+12.1%
- FY1994$4.47B+11.5%
- FY1993$4.01B+11.7%
- FY1992$3.59B+17.7%
- FY1991$3.05B+11.8%
- FY1990$2.73B+28.4%
- FY1989$2.13B-10.0%
- FY1988$2.36B+3.0%
- FY1987$2.29B+9.8%
- FY1986$2.09B+30.6%
- FY1985$1.6B—
Total Liabilities values are taken from Abbott Laboratories's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Liabilities at Abbott Laboratories (ABT)
According to Abbott Laboratories's latest reported financial statements, the company's latest reported total liabilities is $57.5B. Total liabilities sum everything the company owes at the end of each reporting period — accounts payable, accrued expenses, debt, lease obligations, and other claims — as filed on the balance sheet. Compare with total assets and total equity for solvency context.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2025, Abbott Laboratories (ABT) total liabilities totalled $33.9B – edged up 1.3% year-over-year.
Across 2020–2025 (5 years), Abbott Laboratories total liabilities produced a CAGR of -3.0% – with a net decline across the window.
The highest annual total liabilities of $45.2B was reported in 2017. The lowest in the available history was $1.6B in 1985.
Abbott Laboratories Total Liabilities by Year
Abbott Laboratories Total Liabilities 2025: $33.9B
Abbott Laboratories total liabilities in 2025 was $33.9B, edged up 1.3% from 2024.
Abbott Laboratories Total Liabilities 2024: $33.5B
2024's total liabilities for Abbott Laboratories came in at $33.5B, edged down 2.5% below 2023.
Abbott Laboratories Total Liabilities 2023: $34.4B
Abbott Laboratories posted total liabilities of $34.4B in 2023, declined 8.4% below 2022.
Abbott Laboratories Total Liabilities 2022: $37.5B
In 2022, Abbott Laboratories reported total liabilities of $37.5B, edged down 4.2% below 2021.
Abbott Laboratories Total Liabilities 2021: $39.2B
Abbott Laboratories total liabilities in 2021 was $39.2B.
See more financial history for Abbott Laboratories (ABT).
Sector peers by Total Liabilities
Healthcare peers of Abbott Laboratories (ABT), ranked by their latest total liabilities
| $208B | |
| $137B | |
| $118B | |
| $85.9B | |
| $84.2B | |
| $81.9B | |
| $65.4B | |
| $56.8B |
- $137B
- $85.9B
- $84.2B
- $81.9B
- $65.4B
Frequently asked questions
Abbott Laboratories (ABT) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks1.16% TTM
- Dividend Profile2.30% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History9 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.